HitGen Inc., in partnership with Xtalks, is scheduled to host a webinar titled “Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery” on July 17, 2024. The webinar will feature industry experts who will provide insights into the challenges and selection strategies for DNA-encoded library (DEL) technology in the drug discovery process. The objective of this event is to offer a comprehensive understanding of how DEL technology has transformed small-molecule drug discovery.
In recent years, DEL technology has made significant advancements and has played a critical role in identifying hit compounds for drug development. The technology utilizes proteins as targets, sourced from biological samples or expressed in recombinant form, allowing for a wide range of protein constructs. This approach has led to a disruptive hit identification platform, expediting the early-stage small-molecule drug discovery process.
Throughout the webinar, expert speakers will explore the selection of different target types, such as enzymes and receptors, emphasizing the unique advantages and features of DEL technology in their application. Furthermore, they will discuss various DEL platforms and their role in achieving success in the drug discovery process.
A key highlight of the webinar will be a case study presented by BioAge Labs, demonstrating their experience in using DEL technology for the discovery of novel and potent indazole NLRP3 inhibitors. This study, published in Bioorganic & Medicinal Chemistry Letters, illustrates how DEL technology was crucial in identifying small molecule structures, as well as biophysical and biochemical activities, and physicochemical properties for drug discovery purposes.
The webinar offers a valuable opportunity for professionals in the pharmaceutical and biopharmaceutical industries to gain insights into the potential of DEL technology in accelerating drug discovery. It is an event not to be missed for those seeking to stay at the forefront of innovative technologies in drug development.
For those interested in participating in the webinar, registration is available on the official event website. The collaboration between HitGen and Xtalks underscores their dedication to advancing scientific knowledge and technological innovations in the field of drug discovery.
About HitGen Inc.
HitGen Inc. is a prominent drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK, and Houston, USA. The company has established advanced technology platforms for the discovery and optimization of small molecules and nucleic acid drugs, including DNA-encoded library technology (DEL), fragment-based drug discovery, structure-based drug design, synthetic therapeutic oligonucleotide technology, and targeted protein degradation technology. HitGen has a strong track record of collaborations with numerous biopharmaceutical research organizations worldwide, with multiple programs spanning from early discovery to clinical trial stages.
For further information about the webinar and HitGen’s technology platforms, interested parties can contact the Chief Business Officer, Brian Moloney, at +1-760-644-8468 or via email at [email protected]. Alternatively, inquiries can be directed to Alex Shaginian, VP of Business Development & Chemical Sciences, at +1-608-213-5682 or [email protected]. Additional details can also be found on the company’s official website at www.hitgen.com.
Source:
HitGen Inc.